Table 5 SRR (95% CI) of the risk of subsequent cancers in patients exposed to group I pharmaceuticals by publication year.

Cyclosporine

Skin

 ≤ 2010

6^{25,26,27,28,30,31}

1.61 (1.08–2.42)^H

 > 2010

7^{20,21,22,23,24,29,32}

1.25 (0.91–1.70)^H

Hematologic

 ≤ 2010

1³³

0.80 (0.61–1.05)

 > 2010

5^{20,34,35,36,37}

0.99 (0.88–1.11)^L

Azathioprine

Skin

 ≤ 2010

4^25,27,28,31

1.59 (1.07–2.38)^H

 > 2010

9^{21,22,23,24,29,38,39,40,41}

1.58 (1.19–2.10)^L

Hematologic

 ≤ 2010

5^{33,42,43,44,47}

1.55 (0.90–2.69)^H

 > 2010

7^{34,35,36,37,38,45,46}

1.56 (0.93–2.61)^H

Cyclophosphamide

Bladder

 ≤ 2010

2^48,49

4.00 (1.99–8.02)^L

 > 2010

1⁵⁰

1.09 (0.30–3.97)

Hematologic

 ≤ 2010

6^{43,44,51,52,53,54}

2.56 (1.70–3.86)^I

 > 2010

1⁵⁰

1.20 (0.28–5.09)

Busulfan

Hematologic

 ≤ 2010

2^55,56

6.71 (2.49–18.08)^L

Chlorambucil

Hematologic

 ≤ 2010

2^52,54

1.32 (0.81–2.16)^L

Methoxsalen + UV

Skin

 ≤ 2010

1⁵⁷

6.50 (1.40–31.40)

Melphalan

Hematologic

 ≤ 2010

3^51,52,58

4.43 (1.30–15.15)^H

MOPP

Lung

 ≤ 2010

1⁵⁹

5.00 (2.10–13.60)

Etoposide

Hematologic

 ≤ 2010

1⁶⁰

2.70 (1.20–6.00)

Thiotepa

Hematologic

 ≤ 2010

1⁵²

1.82 (1.09–3.03)